METHOD FOR DIFFERENTIAL DIAGNOSIS OF CHRONIC HEPATITIS B AND CHRONIC HEPATITIS C IN PATIENTS WITH SEVERE FIBROSIS AND CIRRHOSIS Russian patent published in 2025 - IPC G01N33/68 G01N33/573 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to hepatology, laboratory diagnostics, and can be used for differential diagnosis of chronic hepatitis B (CHB) and chronic hepatitis C (CHC) in patients with severe fibrosis and cirrhosis. Blood plasma is analysed for concentration of cytokines IL-10 in pg/ml, FGF-2 in pg/ml, IFN2α in pg/ml. Diagnosis in a patient with severe fibrosis and cirrhosis is established by comparing the obtained values with threshold values: at the first stage, the concentration of IFN2α is evaluated, value of which is less than 96.50 pg/ml requires a second stage for this patient, value greater than or equal to 96.50 pg/ml requires a third stage for this patient. At the second stage, the FGF-2 concentration is assessed; if the value is less than 57.26 pg/ml, CHB is diagnosed, and if the value is more than or equal to 57.26, CHC is diagnosed. At the third stage, the IL-10 concentration is assessed; if the value is less than 14.74 pg/ml, CHC is diagnosed; if the value is more than or equal to 14.74, CHB is diagnosed.

EFFECT: method enables determining the cause of developing severe fibrosis and cirrhosis, which enables to divide patients into groups corresponding to the diagnosis of chronic hepatitis C or chronic hepatitis B, by determining three cytokines in blood plasma: IL-10, FGF-2 – fibroblast growth factor 2 and IFN2α.

1 cl, 1 dwg, 3 ex